Literature DB >> 31637536

Ubiquitin-specific peptidase 39 regulates the process of proliferation and migration of human ovarian cancer via p53/p21 pathway and EMT.

Congcong Yan1, Jiahui Yuan1, Jiajia Xu1, Gongye Zhang1, Xiaomei Li1, Bing Zhang2, Tianhui Hu1, Xiaohua Huang2, Yubin Mao3,4, Gang Song5.   

Abstract

Ovarian cancer is one of the most lethal gynecological cancers; owning to its late detection and chemoresistance, understanding the pathogenesis of this malignant tumor is much critical. Previous studies have reported that ubiquitin-specific peptidase 39 (USP39) is generally overexpressed in a variety of cancers, including hepatocellular carcinoma, gastric cancer and so forth. Furthermore, USP39 is proved to be associated with the proliferation of malignant tumors. However, the function and mechanism of USP39 in ovarian cancer have not been elucidated. In the present study, we observed that USP39 was frequently overexpressed in human ovarian cancer and was highly correlated with TNM stage. Suppression of USP39 markedly inhibited the growth and migration of ovarian cancer cell lines HO-8910 and SKOV3 and induced cell cycle G2/M arrest. Moreover, knockdown of USP39 inhibited ovarian tumor growth in a xenograft model. In addition, our findings indicated that cell cycle arrest induced by USP39 knockdown might be involved in p53/p21 signaling pathway. Furthermore, we found that the depletion of USP39 inhibited the migration of ovarian cancer cells via blocking epithelial-mesenchymal transition. Taken together, these results suggest that USP39 may play vital roles in the genesis and progression and may serve as a potential biomarker for diagnosis and therapeutic target of ovarian cancer.

Entities:  

Keywords:  EMT; Growth and migration; Human ovarian cancer; USP39; p53/p21 pathway

Mesh:

Substances:

Year:  2019        PMID: 31637536     DOI: 10.1007/s12032-019-1308-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 2.  Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors.

Authors:  Michael D Gordon; Roel Nusse
Journal:  J Biol Chem       Date:  2006-06-22       Impact factor: 5.157

Review 3.  Wnt/beta-catenin signaling: components, mechanisms, and diseases.

Authors:  Bryan T MacDonald; Keiko Tamai; Xi He
Journal:  Dev Cell       Date:  2009-07       Impact factor: 12.270

4.  Lentivirus-mediated inhibition of USP39 suppresses the growth of breast cancer cells in vitro.

Authors:  Haibo Wang; Xiaojun Ji; Xiangping Liu; Ruyong Yao; Jingwei Chi; Shihai Liu; Yu Wang; Weihong Cao; Quan Zhou
Journal:  Oncol Rep       Date:  2013-10-14       Impact factor: 3.906

Review 5.  Universal control mechanism regulating onset of M-phase.

Authors:  P Nurse
Journal:  Nature       Date:  1990-04-05       Impact factor: 49.962

6.  Important role of SUMOylation of Spliceosome factors in prostate cancer cells.

Authors:  Donghua Wen; Zhijian Xu; Li Xia; Xinyi Liu; Yaoyao Tu; Hu Lei; Weiwei Wang; Tongdan Wang; Lili Song; Chunmin Ma; Hanzhang Xu; Weiliang Zhu; Guoqiang Chen; Yingli Wu
Journal:  J Proteome Res       Date:  2014-07-24       Impact factor: 4.466

7.  beta-Catenin regulates the expression of tenascin-C in human colorectal tumors.

Authors:  Katharina Beiter; Elke Hiendlmeyer; Thomas Brabletz; Falk Hlubek; Angela Haynl; Claudia Knoll; Thomas Kirchner; Andreas Jung
Journal:  Oncogene       Date:  2005-12-08       Impact factor: 9.867

8.  Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53.

Authors:  Saurabh Dayal; Alison Sparks; Jimmy Jacob; Nerea Allende-Vega; David P Lane; Mark K Saville
Journal:  J Biol Chem       Date:  2008-12-19       Impact factor: 5.157

9.  Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.

Authors:  Viktor Horváth; Karel Soucek; Lenka Svihálková-Sindlerová; Jan Vondrácek; Olga Blanárová; Jirina Hofmanová; Petr Sova; Alois Kozubík
Journal:  Invest New Drugs       Date:  2007-05-23       Impact factor: 3.850

10.  The crystal structure of S. cerevisiae Sad1, a catalytically inactive deubiquitinase that is broadly required for pre-mRNA splicing.

Authors:  Haralambos Hadjivassiliou; Oren S Rosenberg; Christine Guthrie
Journal:  RNA       Date:  2014-03-28       Impact factor: 4.942

View more
  5 in total

1.  Ubiquitin specific peptidase 38 promotes the progression of gastric cancer through upregulation of fatty acid synthase.

Authors:  Zhi Zheng; Yuxi Shang; Rui Xu; Xiaosheng Yan; Xi Wang; Jun Cai; Zhigang Bai; Xiaoye Liu; Jie Yin; Jun Zhang; Zhongtao Zhang
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

2.  Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2.

Authors:  Shourong Wang; Zixiang Wang; Jieyin Li; Junchao Qin; Jianping Song; Yingwei Li; Ling Zhao; Xiyu Zhang; Haiyang Guo; Changshun Shao; Beihua Kong; Zhaojian Liu
Journal:  Cell Death Dis       Date:  2021-03-17       Impact factor: 8.469

3.  High Expression of Ubiquitin-Specific Protease 39 and Its Roles in Prognosis in Patients with Hepatocellular Carcinoma.

Authors:  Yu Liao; Lin Li; Huabao Liu; Yi Song
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-27       Impact factor: 2.629

Review 4.  Identifying Novel Actionable Targets in Colon Cancer.

Authors:  Maria Grazia Cerrito; Emanuela Grassilli
Journal:  Biomedicines       Date:  2021-05-20

5.  Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma.

Authors:  Xiaomei Li; Jiahui Yuan; Conghua Song; Yongbin Lei; Jiajia Xu; Gongye Zhang; Weiwei Wang; Gang Song
Journal:  Cell Death Differ       Date:  2021-03-01       Impact factor: 15.828

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.